S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
NASDAQ:TECH

Bio-Techne (TECH) Stock Forecast, Price & News

$69.35
-0.57 (-0.82%)
(As of 09/22/2023 ET)
Compare
Today's Range
$69.20
$70.12
50-Day Range
$69.35
$89.42
52-Week Range
$68.00
$90.63
Volume
1.05 million shs
Average Volume
972,411 shs
Market Capitalization
$10.97 billion
P/E Ratio
39.35
Dividend Yield
0.46%
Price Target
$101.58

Bio-Techne MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
46.5% Upside
$101.58 Price Target
Short Interest
Healthy
1.96% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-1.30
Upright™ Environmental Score
News Sentiment
0.96mentions of Bio-Techne in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$7.79 M Sold Last Quarter
Proj. Earnings Growth
18.39%
From $1.74 to $2.06 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.23 out of 5 stars

Medical Sector

15th out of 968 stocks

Biological Products, Except Diagnostic Industry

2nd out of 160 stocks


TECH stock logo

About Bio-Techne (NASDAQ:TECH) Stock

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

TECH Price History

TECH Stock News Headlines

[BREAKING] New "Living Software" to Revolutionize Warfare
This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>
Most Stocks in S&P 500 Are Rising Monday
[BREAKING] New "Living Software" to Revolutionize Warfare
This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>
BIO-TECHNE ANNOUNCES 2023 INVESTOR DAY AND WEBCAST
Is Bio-Techne Corp (TECH) Modestly Undervalued?
BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2023 RESULTS
See More Headlines
Receive TECH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Techne and its competitors with MarketBeat's FREE daily newsletter.

TECH Company Calendar

Last Earnings
8/08/2023
Ex-Dividend for 9/1 Dividend
8/17/2023
Dividend Payable
9/01/2023
Today
9/22/2023
Next Earnings (Estimated)
11/07/2023
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:TECH
CUSIP
87837710
Employees
3,050
Year Founded
1981

Price Target and Rating

Average Stock Price Forecast
$101.58
High Stock Price Forecast
$120.00
Low Stock Price Forecast
$86.00
Forecasted Upside/Downside
+46.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Net Income
$285.26 million
Pretax Margin
29.79%

Debt

Sales & Book Value

Annual Sales
$1.14 billion
Cash Flow
$2.46 per share
Book Value
$12.49 per share

Miscellaneous

Free Float
151,198,000
Market Cap
$10.97 billion
Optionable
Optionable
Beta
1.21

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Charles R. KummethMr. Charles R. Kummeth (Age 63)
    CEO, Pres & Director
    Comp: $1.26M
  • Mr. James T. HippelMr. James T. Hippel (Age 52)
    Exec. VP of Fin. & CFO
    Comp: $691.78k
  • Mr. Shane Bohnen (Age 48)
    Sr. VP, Gen. Counsel & Corp. Sec.
    Comp: $353.6k
  • Mr. Kim KeldermanMr. Kim Kelderman (Age 56)
    Pres of Diagnostics & Genomics
    Comp: $845.71k
  • Mr. William A. Geist (Age 53)
    Pres of Protein Sciences Segment
    Comp: $533.67k
  • David Clair
    Sr. Director of Investor Relations & Corp. Devel.
  • Mr. Gerry Andros
    VP of Sales and Marketing
  • Mr. Robert M. Gavin (Age 55)
    VP of Corp. Devel.
  • Ms. Brenda S. Everson
    Sr. VP & Chief HR Officer
  • Mr. Luca Cicchetti
    Managing Director













TECH Stock - Frequently Asked Questions

Should I buy or sell Bio-Techne stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Techne in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TECH shares.
View TECH analyst ratings
or view top-rated stocks.

What is Bio-Techne's stock price forecast for 2023?

9 brokerages have issued 1 year price objectives for Bio-Techne's shares. Their TECH share price forecasts range from $86.00 to $120.00. On average, they anticipate the company's stock price to reach $101.58 in the next year. This suggests a possible upside of 46.5% from the stock's current price.
View analysts price targets for TECH
or view top-rated stocks among Wall Street analysts.

How have TECH shares performed in 2023?

Bio-Techne's stock was trading at $82.88 at the beginning of 2023. Since then, TECH stock has decreased by 16.3% and is now trading at $69.35.
View the best growth stocks for 2023 here
.

When is Bio-Techne's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our TECH earnings forecast
.

How were Bio-Techne's earnings last quarter?

Bio-Techne Co. (NASDAQ:TECH) posted its quarterly earnings results on Tuesday, August, 8th. The biotechnology company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.49 by $0.07. The biotechnology company earned $301.32 million during the quarter, compared to the consensus estimate of $304.71 million. Bio-Techne had a net margin of 25.10% and a trailing twelve-month return on equity of 15.47%.

How often does Bio-Techne pay dividends? What is the dividend yield for Bio-Techne?

Bio-Techne declared a quarterly dividend on Tuesday, August 8th. Shareholders of record on Friday, August 18th will be paid a dividend of $0.08 per share on Friday, September 1st. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.46%. The ex-dividend date is Thursday, August 17th.
Read our dividend analysis for TECH
.

Is Bio-Techne a good dividend stock?

Bio-Techne (NASDAQ:TECH) pays an annual dividend of $0.32 per share and currently has a dividend yield of 0.45%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 18.16%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, TECH will have a dividend payout ratio of 15.53% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for TECH.

When did Bio-Techne's stock split?

Bio-Techne's stock split before market open on Wednesday, November 30th 2022. The 4-1 split was announced on Tuesday, November 1st 2022. The newly issued shares were distributed to shareholders after the market closes on Tuesday, November 29th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

What is Charles Kummeth's approval rating as Bio-Techne's CEO?

95 employees have rated Bio-Techne Chief Executive Officer Charles Kummeth on Glassdoor.com. Charles Kummeth has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Bio-Techne own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Techne investors own include Paychex (PAYX), Gilead Sciences (gild), NVIDIA (NVDA), AbbVie (ABBV), Amgen (AMGN), Abbott Laboratories (ABT), Cisco Systems (CSCO), Johnson & Johnson (JNJ), AT&T (T) and Boeing (BA).

What is Bio-Techne's stock symbol?

Bio-Techne trades on the NASDAQ under the ticker symbol "TECH."

Who are Bio-Techne's major shareholders?

Bio-Techne's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (10.74%), State Street Corp (4.07%), Geode Capital Management LLC (2.25%), Brown Capital Management LLC (2.01%), William Blair Investment Management LLC (1.47%) and Ownership Capital B.V. (1.45%). Insiders that own company stock include Alpna Seth, Brenda S Furlow, Brenda S Furlow, Charles R Kummeth, Charles R Kummeth, Glenn Hedde, James Hippel, John L Higgins, Kim Kelderman, Norman David Eansor, Robert V Baumgartner and Roeland Nusse.
View institutional ownership trends
.

How do I buy shares of Bio-Techne?

Shares of TECH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bio-Techne's stock price today?

One share of TECH stock can currently be purchased for approximately $69.35.

How much money does Bio-Techne make?

Bio-Techne (NASDAQ:TECH) has a market capitalization of $10.97 billion and generates $1.14 billion in revenue each year. The biotechnology company earns $285.26 million in net income (profit) each year or $1.7625 on an earnings per share basis.

How many employees does Bio-Techne have?

The company employs 3,050 workers across the globe.

Does Bio-Techne have any subsidiaries?
The following companies are subsidiares of Bio-Techne: Advanced Cell Diagnostics, Advanced Cell Diagnostics Inc., B-MoGen Biotechnologies Inc., Bio-Techne China Co. Ltd, Bio-Techne Ltd., Bionostics Inc., Cliniqa, CyVek, Exosome Diagnostics, Exosome Diagnostics Inc., MoGen Biotechnologies, Novus Biologicals, Novus Biologicals LLC, ProteinSimple, ProteinSimple Ltd., QT Holdings Corporation, Quad Technologies, Research and Diagnostic Systems Inc., Shanghai PrimeGene Bio-Tech Co. Ltd., Space Import-Export Srl, Tocris Cookson Limited, and Zephyrus Biosciences.
Read More
How can I contact Bio-Techne?

Bio-Techne's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The official website for the company is www.bio-techne.com. The biotechnology company can be reached via phone at (612) 379-8854, via email at ir@bio-techne.com, or via fax at 612-656-4400.

This page (NASDAQ:TECH) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -